Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Trial details
- Registry ID
- NCT06050122
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Placebo; Vehicle Gel
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122 | SLGL | Phase 3 | Completed | 2026-08-20Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |